Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 2, Issue 1
Abstract
Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for clinicians. The current guidelines offer a variety of options in the first and second line for metastatic breast cancer. A tailored treatment approach is needed for the triple-positive metastatic breast cancer population. Objective To trend the therapeutic treatment selections for patients with metastatic, triple-positive breast cancer at a single, community practice. Methods: The Abington Jefferson Health Tumor Registry and electronic medical records systems were used to retrospectively identify patients with hormone and HER-2 positive metastatic disease who were treated at Abington Jefferson Health between 2010-2016. Results: It was found that there was variability across our population in the choice of what therapy was chosen for first, second and fourth line of treatment. The majority of patients (12 out of 15) received combination therapy with trastuzumab. In the second line, 7 out 8 patients received trastuzumab as part of their treatment regimen. In the third line, all 3 patients received trastuzumab emtansine as part of their therapy regimen. For patients who were able to survive until the fourth line and beyond, several other treatments were used. Limitations: A small sample size is the major limitation in this study. Conclusion: Although HR+/ Her2+ (triple positive) cancer cell type represents a subset of patients with metastatic breast cancer, there is a general lack of consensus on how to best treat this patient population. More research needs to be conducted in order for community Oncologic practitioners to be able to better coordinate care for patients with triple positive, metastatic breast cancer.
Authors and Affiliations
Ida Micaily, Lakshmi Kolandra, Shahrzad Abdollahi, Anthony Scarpaci
Keywords
Related Articles
- EP ID EP587898
- DOI 10.32474/OAJOM.2018.02.000127
- Views 66
- Downloads 0
Breast Cancer Screening in the United Arab Emirates: Is it Time to Call for a Screening at an Earlier Age?
Cancer is a major health issue around the world, in the United Arab Emirates ( UAE ) it is the 3rd leading cause of death after cardiovascular diseases and injuries, accounting for 10% of all mortalities in the UAE in 20...
Subjection between Breast Cancer and Body Mass Index, the Role of L-Carnitine in Prediction and Outcomes of the Disease
Increasing the effectiveness of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic antitumor therapy compared with patients receiving standard neoadjuvant systemic antitumor the...
Thrombosis in Iron Deficiency and Iron Deficiency Anemia: A Review of our Cases and the Relevant Literature
We evaluated our thrombosis cases for iron deficiency (ID) or iron deficiency anemia (IDA) retrospectively and reviewed the literature. We established that iron parameters were studied in 17 of 64 patients with thrombosi...
Main Components of Liquid Biopsy are Greater than it Seems?
Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to met...
Hydrogen Peroxide and Cancer
I’ll share an antidotal observation that may prove useful to cancer researchers. I studied hyper-ferritism and Ferric Chloride to see its possible link to schizophrenia. Those results are well published [1,2]. However, I...